Research programme: cyclin dependent kinase inhibitors - G1 Therapeutics

Drug Profile

Research programme: cyclin dependent kinase inhibitors - G1 Therapeutics

Alternative Names: Chemoprotection therapies - G1 Therapeutics; Pharmacoquiescence (PQ™); Radioprotection therapies - G1 Therapeutics

Latest Information Update: 25 Oct 2013

Price : $50

At a glance

  • Originator G1 Therapeutics
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Chemoprotection; Radioprotection

Most Recent Events

  • 16 Oct 2013 Preclinical development in Chemotherapy induced damage/Chemoprotection is ongoing
  • 19 Sep 2012 Preclinical trials in Radiation injuries/Radioprotection in USA (PO)
  • 19 Sep 2012 Preclinical trials in Chemotherapy induced damage/Chemoprotection in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top